NIMD

Noninvasive, Localized Hyperthermia for Treating Cancer

Health Tech & Life Sciences
Non Active, Nov 2018 ceased to operate
Seed Jerusalem, Israel Founded 2015
LinkedIn
Last updated 2026-06-18
Total raised
$700K
Last: 2015-05
Stage
Seed
Founded
2015
Headcount
1-10
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Noninvasive Medical Devices (NIMD) is a medical device start-up company that develops localized microwave thermal ablation devices to treat cancer. Its technology is based on a noninvasive localized microwave heating applicator coupled with nanoparticles placed inside the tumor. NIMDs device is designed to deliver the lowest microwave energy and highest accuracy for cancer treatment, and may also be used to detect cancer at an early stage. Hyperthermed is the companys first compact, versatile medical device and can be used in hospitals and cancer clinics to treat specific types of cancer using localized hyperthermia. Hyperthermed selectively targets cancer cells with no damage to the surrounding healthy tissue. The product also noninvasively images and monitors the tumor temperature. NIMD is currently focusing on breast cancer treatment, but its technology may also be applicable for skin melanomas; glioblastomas; chest, tongue, head, and neck cancers; and lung cancer. The company, located in Jerusalem, is at the preclinical stage and has demonstrated its proof of concept on animals.

Funding history · 1 round · $700K total

2015-05
$700K

Q&A

What is NIMD's primary focus in medical device development?
NIMD is a medical device startup that develops localized microwave thermal ablation devices for cancer treatment, specifically focusing on noninvasive methods.
What is the name of NIMD's first medical device product?
NIMD's first compact, versatile medical device is called Hyperthermed, designed for localized hyperthermia treatment in hospitals and cancer clinics.
Which types of cancer is NIMD's technology primarily targeting?
NIMD is currently focusing on breast cancer treatment, with potential applicability for skin melanomas, glioblastomas, and various head, neck, and lung cancers.
What is the current development stage of NIMD's technology?
NIMD's technology is at the preclinical stage and has demonstrated its proof of concept on animals.
When was NIMD founded?
NIMD was founded in January 2015.
What is NIMD's total funding raised to date?
NIMD has raised a total of $700,000 USD.
When did NIMD complete its last funding round?
NIMD completed its last funding round in May 2015, raising $700,000 USD.
What is the operational status of NIMD?
NIMD is currently inactive, having ceased operations in November 2018.

Team · 1

Founder · Founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
ConsumersDemographics & FamilyWomenHealthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

Verified

Tags

non-invasivemedical-devicesclinicsoncologycancermedical-technologieshospitalsnanotechnologymonitoringimagingwomen-healthdiagnosticstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)